No abstract available
Publication types
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Bevacizumab
-
Clinical Protocols
-
Diabetic Retinopathy / drug therapy*
-
Diabetic Retinopathy / physiopathology
-
Double-Blind Method
-
Female
-
Humans
-
Intravitreal Injections
-
Macular Edema / drug therapy*
-
Macular Edema / physiopathology
-
Male
-
Middle Aged
-
Randomized Controlled Trials as Topic
-
Ranibizumab
-
Receptors, Vascular Endothelial Growth Factor / adverse effects
-
Receptors, Vascular Endothelial Growth Factor / therapeutic use*
-
Recombinant Fusion Proteins / adverse effects
-
Recombinant Fusion Proteins / therapeutic use*
-
Therapeutic Equivalency
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Visual Acuity / physiology
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Recombinant Fusion Proteins
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
aflibercept
-
Bevacizumab
-
Receptors, Vascular Endothelial Growth Factor
-
Ranibizumab